PMID- 38129782
OWN - NLM
STAT- MEDLINE
DCOM- 20231225
LR  - 20231225
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Dec 21
TI  - Preliminary evidence for endoscopic surgery combined with postoperative anti-PD-1 
      immunotherapy in advanced recurrent nasopharyngeal carcinoma.
PG  - 1259
LID - 10.1186/s12885-023-11760-y [doi]
LID - 1259
AB  - BACKGROUD: Endoscopic surgery can be used as the main treatment for advanced 
      recurrent nasopharyngeal carcinoma (rNPC). However, there is a huge clinical 
      controversy about the need for consolidated immunotherapy after surgery. METHODS: 
      We performed a retrospective propensity score-matched analysis (1:2) of patients 
      with locally advanced rNPC who underwent endoscopic nasopharyngectomy (ENPG) 
      combined with anti-programmed cell death protein-1 (PD-1) monotherapy or ENPG 
      alone. The survival rate was analyzed by Kaplan-Meier method. The primary 
      endpoint was progression-free survival (PFS). The secondary endpoints included 
      overall survival (OS), objective response rate (ORR) and disease control rate 
      (DCR). Potential surgical-related complications and immune-related adverse events 
      (AEs) were also assessed. RESULTS: We recruited 10 patients receiving ENPG plus 
      anti-PD-1 monotherapy and 20 receiving ENPG alone. During the mean follow-up of 
      23.8 months, a significant improvement in the 2-year PFS was detected in the 
      consolidation immunotherapy group compared to the ENPG alone group (80.0% vs. 
      40.0%; HR = 0.258; 95% CI: 0.09-0.72; p = 0.04), while the 2-year OS in the 
      consolidation immunotherapy group was not significantly longer than that in the 
      ENPG alone group (90.0% vs. 75.0%; HR = 0.482; 95% CI: 0.08-3.00; p = 0.50). The 
      incidence of surgical-related complications in the consolidation immunotherapy 
      group and ENPG alone group was 70.0 and 60.0%, respectively. Immune-related AEs 
      were similar between the toripalimab arm (75.0%) and the camrelizumab arm 
      (66.7%). Surgical-related complications depend on symptomatic treatments. 
      Immune-related AEs were mild and tolerable. CONCLUSIONS: Consolidation 
      immunotherapy regimen for patients with advanced rNPC after ENPG compared to ENPG 
      alone provides a superior PFS rate with a manageable safety profile.
CI  - (c) 2023. The Author(s).
FAU - Xu, Haoyuan
AU  - Xu H
AD  - ENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan 
      University, Shanghai, 200031, China.
FAU - Li, Wanpeng
AU  - Li W
AD  - ENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan 
      University, Shanghai, 200031, China.
FAU - Zhang, Huankang
AU  - Zhang H
AD  - ENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan 
      University, Shanghai, 200031, China.
FAU - Wang, Huan
AU  - Wang H
AD  - ENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan 
      University, Shanghai, 200031, China.
FAU - Hu, Li
AU  - Hu L
AD  - ENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan 
      University, Shanghai, 200031, China.
FAU - Gu, Yurong
AU  - Gu Y
AD  - ENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan 
      University, Shanghai, 200031, China. graceyrgu@hotmail.com.
FAU - Wang, Dehui
AU  - Wang D
AD  - ENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan 
      University, Shanghai, 200031, China. wangdehuient@sina.com.
LA  - eng
PT  - Journal Article
DEP - 20231221
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
SB  - IM
MH  - Humans
MH  - Nasopharyngeal Carcinoma/drug therapy
MH  - Retrospective Studies
MH  - Progression-Free Survival
MH  - *Nasopharyngeal Neoplasms/drug therapy/surgery
MH  - Immunotherapy/adverse effects
PMC - PMC10734134
OTO - NOTNLM
OT  - Anti-PD-1 immunotherapy
OT  - Endoscopic surgery
OT  - Propensity score matching
OT  - Recurrent nasopharyngeal carcinoma
OT  - Survival
COIS- The authors declare no competing interests.
EDAT- 2023/12/22 06:43
MHDA- 2023/12/25 06:42
PMCR- 2023/12/21
CRDT- 2023/12/22 00:17
PHST- 2023/09/09 00:00 [received]
PHST- 2023/12/14 00:00 [accepted]
PHST- 2023/12/25 06:42 [medline]
PHST- 2023/12/22 06:43 [pubmed]
PHST- 2023/12/22 00:17 [entrez]
PHST- 2023/12/21 00:00 [pmc-release]
AID - 10.1186/s12885-023-11760-y [pii]
AID - 11760 [pii]
AID - 10.1186/s12885-023-11760-y [doi]
PST - epublish
SO  - BMC Cancer. 2023 Dec 21;23(1):1259. doi: 10.1186/s12885-023-11760-y.